Research Article
Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center
Table 10
Systemic pharmacotherapy for the immune-mediated inflammatory disease at the time of survey.
| | | With history of COVID-19† | Without history of COVID-19† | Chi2 | | No. | (IBD/RD) | % | No. | (IBD/RD) | % |
| | | 81 | | 100 | 72 | | 100 | | | Azathioprine | 12 | (12/0) | 14.8 | 11 | (9/2) | 15.3 | 1 | | Mycophenolate | 5 | (0/5) | 6.2 | 0 | | — | 0.09 | | Methotrexate | 5 | (0/5) | 6.2 | 5 | (0/5) | 6.9 | 1 | | Hydroxychloroquine | 3 | (0/3) | 3.7 | 1 | (0/1) | 1.4 | 0.70 | | Systemic glucocorticoid | 11 | (3/8) | 13.6 | 22 | (13/9) | 30.6 | | | Biologic agent | 35 | (23/12) | 43.2 | 36 | (30/6) | 50.0 | 0.50 | | Adalimumab | 9 | (6/3) | 11.1 | 14 | (13/1) | 19.4 | | | Infliximab | 11 | (8/3) | 13.6 | 6 | (4/2) | 8.3 | | | Etanercept | 2 | (0/2) | 2.5 | 0 | | — | | | Ustekinumab | 2 | (1/1) | 2.5 | 2 | (2/0) | 2.8 | | | Vedolizumab | 8 | (8/0) | 9.9 | 11 | (11/0) | 15.3 | | | Rituximab | 1 | (0/1) | 1.2 | 2 | (0/2) | 2.8 | | | Belimumab | 2 | (0/2) | 2.5 | 0 | | — | | | Abatacept | 0 | | — | 1 | (0/1) | 1.4 | | | Janus kinase inhibitor (e.g., upadacitinib) | 2 | (0/2) | 2.5 | 2 | (0/2) | 2.8 | 1 |
|
|
†data obtained by 153 patients; COVID-19: coronavirus disease 2019; IBD: inflammatory bowel disease; RD: rheumatic disease . |
